India Pharma Outlook Team | Monday, 15 September 2025
AstraZeneca has announced today landmark data from the Phase III FLAURA2 trial, demonstrating that its targeted therapy, Tagrisso (osimertinib), plus pemetrexed and platinum-based chemotherapy, achieved the longest overall survival reported in any global Phase III study for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC).
The final data, presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona, showed a median overall survival (OS) of 47.5 months—nearly 4 years—for the Tagrisso, pemetrexed, and platinum-based chemotherapy combination.
The OS for Tagrisso monotherapy was 37.6 months. This represents a major breakthrough compared to the standard survival established by the original FLAURA trial, which established Tagrisso as the first-line standard of care.
Also Read: Role of Optical Imaging in Early Cancer Detection and Treatment
David Planchard, MD, PhD, Thoracic Oncologist at Gustave Roussy Institute of Oncology in Villejuif, France, and principal investigator of the trial, said: “The fundamental goals of lung cancer treatment are to extend survival while preserving patients’ quality of life…With two highly effective options, physicians can better tailor treatment to individual patient needs and maximize outcomes.”
Susan Galbraith, Executive Vice President, Oncology R&D at AstraZeneca, said, “The FLAURA2 final analysis sets a new survival benchmark in EGFR-mutated advanced lung cancer, with Tagrisso plus chemotherapy extending median overall … of non-small cell lung cancer. These results reinforce Tagrisso’s role as the backbone of treatment in EGFR-mutated lung cancer.”
With these landmark data, Tagrisso continues to establish itself as a global standard of care and an important backbone for subsequent treatment approaches in advanced lung cancer.
